Cyrus M. Khan, MD, discussed recent advancements in CLL treatment, particularly the shift to nonchemotherapy options and the ...

A comparison of the second-generation Bruton tyrosine kinase (BTK) inhibitor acalabrutinib to the first-generation ibrutinib shows the former had lower rates of adverse events in a real-world ...

Susan L. Slager, PhD, discussed the etiology and inherited genetic factors that are associated with the risk of chronic ...

Mike Peters says his future is unclear as he loses his chance for a stem cell donation.

The frontman of Welsh rock band The Alarm is facing an uncertain future after his rare aggressive cancer returned. Mike ...

The Prestatyn-born rock star was given the all-clear earlier this year - but his rare and aggressive lymphoma returned last ...

The long-term response rate for zanubrutinib was better than ibrutinib in patients with relapsed/refractory chronic ...

The rock star, who was forced to cancel a US tour earlier this year after being diagnosed with fast-growing lymphoma, was ...

As an internationally-recognized expert in lymphoma, CLL, and cellular therapy, Dr. Patel’s research has been highlighted in ...

The FDA granted a fast track designation to BGB-16673, a novel drug used to treat chronic lymphocytic leukemia and small lymphocytic lymphoma. After having SLL for 15 years, I won't let it define me — ...

Detailed price information for Adaptive Biotechnologies Corp (ADPT-Q) from The Globe and Mail including charting and trades.

CLL or small lymphocytic lymphoma (SLL), with no new safety signals observed; detailed data will be presented at the annual ...